Analysis of the EAP, page-97

Catching up on earlier posts. . Remdesivir had an EAP and then several follow on trials. One compared 5 days to 10 days of Rx and documented no benefit to the 10 days.... So 5 days is now recommended, with physician discretion to continue for 10 days...I guess if trying for placebo effect. A second study conducted under auspices of NIAID (Dr Fauci's organization) was placebo controlled and blinded. Interim results showed a reduction in average length of illness from 15 to 11 days. There was only a slight reduction in mortality, not statistically significant. (The latter is the rem-L target population). Based on those results an EUA was granted. The trial continues and the med remains unapproved, must be distributed through gov't agencies with careful documentation, etc.